Implications of intracellular distribution of nanovesicles for bioimaging studies

Journal of Biomedical Nanotechnology

Volumn 5, Issue 6, 2009, Pages 620-633

  Elbayoumi, Tamer ^a   Weissig, Volkmar ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Caveolae; Clathrin; Confocal microscopy; Endocytosis; Liposomes; Micelles; Multi spectral microscopy; Protein transduction domains; Raman microspectroscopy; Theranostic

Indexed keywords

CAVEOLAE; CLATHRIN; CLATHRINS; ENDOCYTOSIS; MULTI-SPECTRAL; PROTEIN TRANSDUCTION DOMAINS; RAMAN MICROSPECTROSCOPY;

BACTERIOPHAGES; CONFOCAL MICROSCOPY; DENDRIMERS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MICELLES; PHOSPHOLIPIDS; PROTEINS; SEMICONDUCTOR QUANTUM DOTS;

NANOSTRUCTURED MATERIALS;

LIPOSOME; NANOCARRIER; NANOMATERIAL;

CELL FUNCTION; CELL MEMBRANE; CELL MIGRATION; CELL STRUCTURE; CELLULAR DISTRIBUTION; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE TRANSPORT; MOLECULAR IMAGING; NONHUMAN; PARTICLE SIZE; PHOSPHOLIPID VESICLE; REVIEW; TRANSPORT VESICLE;

CONTRAST MEDIA; IMAGE ENHANCEMENT; MICROSCOPY; NANOCAPSULES; PARTICLE SIZE; SUBCELLULAR FRACTIONS;

EID: 76749095125     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2009.1079     Document Type: Review

References (113)

1. V. P. Torchilin, Nanocarriers. Pharm. Res. 24, 2333 (2007).
2. V. P. Torchilin, Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS. J. 9, E128 (2007).
3. T. A. Elbayoumi and V. P. Torchilin, Current trends in liposome research, Liposomes, edited by V. Weissig, Springer and Humana Press, Totowa, NJ, (2009).
4. P. Baum, D. Muller, R. Ruger, and R. E. Kontermann, Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J. Drug Target 15, 399 (2007).
5. D. Sadava, T. Phillips, C. Lin, and S. E. Kane, Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 179, 151 (2002).
6. P. P. Constantinides, M. V. Chaubal, and R. Shorr, Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv. Drug Deliv. Rev. 60, 757 (2008).
7. T. A. Elbayoumi and V. P. Torchilin, Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm. 6, 246 (2009).
8. V. Torchilin, Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur. J. Pharm. Biopharm. 71, 431 (2009).
9. I. A. Khalil, K. Kogure, S. Futaki, and H. Harashima, Octaarginine-modified liposomes: Enhanced cellular uptake and controlled intracellular trafficking. Int. J. Pharm. 354, 39 (2008).
10. D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732 (2006).
11. Y. Kakizawa and K. Kataoka, Block copolymer micelles for delivery of gene and related compounds. Adv. Drug Deliv. Rev. 54, 203 (2002).
12. V. P. Torchilin, Micellar nanocarriers: Pharmaceutical perspectives. Pharm. Res. 24, 1 (2007).
13. V. P. Torchilin, Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv. 2, 319 (2005).
14. V. P. Torchilin, B. A. Khaw, and V. Weissig, Intracellular targets for DNA delivery: Nuclei and mitochondria. Somat. Cell Mol. Genet. 27, 49 (2002).
15. A. R. Thierry, A. Rahman, and A. Dritschilo, Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides. Biochem. Biophys. Res. Commun. 190, 952 (1993).
16. D. Goren, A. T. Horowitz, D. Tzemach, M. Tarshish, S. Zalipsky, and A. Gabizon, Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6, 1949 (2000).
17. D. Kim, E. S. Lee, K. T. Oh, Z. G. Gao, and Y. H. Bae, Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4, 2043 (2008).
18. X. Zhao, H. Li, and R. J. Lee, Targeted drug delivery via folate receptors. Expert Opin. Drug Deliv. 5, 309 (2008).
19. Y. Zhang, X. Rong Qi, Y. Gao, L. Wei, Y. Maitani, and T. Nagai, Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect. J. Control. Release 117, 281 (2007).
20. V. P. Torchilin, Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8, 343 (2006).
21. P. Sapra, and T. M. Allen, Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62, 7190 (2002).
22. A. Brave, D. Hallengard, L. Gudmundsdotter, R. Stout, R. Walters, B. Wahren, and K. Hallermalm, Late administration of plasmid DNA by intradermal electroporation efficiently boosts DNA-primed T and B cell responses to carcinoembryonic antigen. Vaccine 27, 3692 (2009).
23. E. Orias, D. Larson, Y. F. Hu, G. L. Yu, J. Karttunen, A. Lovlie, B. Haller, and E. H. Blackburn, Replacement of the macronuclear ribosomal RNA genes of a mutant Tetrahymena using electroporation. Gene 70, 295 (1988).
24. A. Asokan and M. J. Cho, Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. J. Pharm. Sci. 91, 903 (2002).
25. L. Di Marzio, C. Marianecci, B. Cinque, M. Nazzarri, A. M. Cimini, L. Cristiano, M. G. Cifone, F. Alhaique, and M. Carafa, pH-sensitive non-phospholipid vesicle and macrophage-like cells: Binding, uptake and endocytotic pathway. Biochim. Biophys. Acta. 1778, 2749 (2008).
26. J. Connor, M. B. Yatvin, and L. Huang, pH-sensitive liposomes: Acid-induced liposome fusion. Proc. Natl. Acad. Sci. USA 81, 1715 (1984).
27. E. S. Lee, K. Na, and Y. H. Bae, Polymeric micelle for tumor pH and folate-mediated targeting. J. Control. Release 91, 103 (2003).
28. R. M. Straubinger, N. Duzgunes, and D. Papahadjopoulos, pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS. Lett. 179, 148 (1985).
29. V. P. Torchilin, R. Rammohan, V. Weissig, and T. S. Levchenko, TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA 98, 8786 (2001).
30. C. Foged and H. M. Nielsen, Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin. Drug Deliv. 5, 105 (2008).
31. V. P. Torchilin, Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv. Drug Deliv. Rev. 60, 548 (2008).
32. T. S. Griffith, B. Stokes, T. A. Kucaba, J. K. Earel, Jr., R. L. VanOosten, E. L. Brincks, and L. A. Norian, TRAIL gene therapy: From preclinical development to clinical application. Curr. Gene Ther. 9, 9 (2009).
33. L. Gudmundsdotter, A. Sjodin, A. C. Bostrom, B. Hejdeman, R. Theve-Palm, A. Alaeus, K. Lidman, and B. Wahren, Therapeutic immunization for HIV. Springer Semin. Immunopathol. 28, 221 (2006).
34. R. M. Blaese, Steps toward gene therapy: 1 The initial trials. Hosp. Pract. 30, 33 (1995).
35. K. Aalto-Setala and E. Vuorio, Gene therapy of single-gene disorders: Preface to the special section. Ann. Med. 29, 549 (1997).
36. X. Zhou and L. Huang, DNA transfection mediated by cationic liposomes containing lipopolylysine: Characterization and mechanism of action. Biochim. Biophys. Acta. 1189, 195 (1994).
37. A. Ardehali, A. Fyfe, H. Laks, D. C. Drinkwater, Jr., J. H. Qiao, and A. J. Lusis, Direct gene transfer into donor hearts at the time of harvest. J. Thorac. Cardiovasc. Surg. 109, 716 (1995).
38. M. C. Filion and N. C. Phillips, Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim. Biophys. Acta. 1329, 345 (1997).
39. M. C. Filion and N. C. Phillips, Anti-inflammatory activity of cationic lipids. Br. J. Pharmacol. 122, 551 (1997).
40. H. R. Kim, I. K. Kim, K. H. Bae, S. H. Lee, Y. Lee, and T. G. Park, Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 5, 622 (2008).
41. F. Tang and J. A. Hughes, Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. Bioconjug. Chem. 10, 791 (1999).
42. Y. Xu and F. C. Szoka, Jr., Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry 35, 5616 (1996).
43. S. Sofou and G. Sgouros, Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin. Drug Deliv. 5, 189 (2008).
44. T. A. Elbayoumi and V. P. Torchilin, Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur. J. Nucl. Med. Mol. Imaging. 33, 1196 (2006).
45. T. A. Elbayoumi, S. Pabba, A. Roby, and V. P. Torchilin, Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J. Liposome Res. 17, 1 (2007).
46. R. Saito, J. R. Bringas, T. R. McKnight, M. F. Wendland, C. Mamot, D. C. Drummond, D. B. Kirpotin, J. W. Park, M. S. Berger, and K. S. Bankiewicz, Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res. 64, 2572 (2004).
47. B. Szachowicz-Petelska, Z. Figaszewski, and W. Lewandowski, Mechanisms of transport across cell membranes of complexes contained in antitumour drugs. Int. J. Pharm. 222, 169 (2001).
48. A. T. Jones, M. Gumbleton, and R. Duncan, Understanding endocytic pathways and intracellular trafficking: A prerequisite for effective design of advanced drug delivery systems. Adv. Drug Deliv. Rev. 55, 1353 (2003).
49. S. A. Mousavi, L. Malerod, T. Berg, and R. Kjeken, Clathrin-dependent endocytosis. Biochem. J. 377, 1 (2004).
50. G. Bathori, L. Cervenak, and I. Karadi, Caveolae-An alternative endocytotic pathway for targeted drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 21, 67 (2004).
51. J. Rejman, A. Bragonzi, and M. Conese, Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo-and polyplexes. Mol. Ther. 12, 468 (2005).
52. S. B. Sieczkarski and G. R. Whittaker, Dissecting virus entry via endocytosis. J. Gen. Virol. 83, 1535 (2002).
53. J. Gruenberg, The endocytic pathway: A mosaic of domains. Nat. Rev. Mol. Cell Biol. 2, 721 (2001).
54. C. M. Varga, T. J. Wickham, and D. A. Lauffenburger, Receptor-mediated targeting of gene delivery vectors: Insights from molecular mechanisms for improved vehicle design. Biotechnol. Bioeng. 70, 593 (2000).
55. R. I. Mahato, Y. Takakura, and M. Hashida, Development of targeted delivery systems for nucleic acid drugs. J. Drug Target. 4, 337 (1997).
56. U. S. Huth, R. Schubert, and R. Peschka-Suss, Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J. Control. Release 110, 490 (2006).
57. V. P. Torchilin, Fluorescence microscopy to follow the targeting of liposomes and micelles to cells and their intracellular fate. Adv. Drug Deliv. Rev. 57, 95 (2005).
58. L. Tong, Y. Lu, R. J. Lee, and J. X. Cheng, Imaging receptor-mediated endocytosis with a polymeric nanoparticle-based coherent anti-stokes Raman scattering probe. J. Phys. Chem. B 111, 9980 (2007).
59. C. Matthaus, A. Kale, T. Chernenko, V. Torchilin, and M. Diem, New ways of imaging uptake and intracellular fate of liposomal drug carrier systems inside individual cells, based on Raman microscopy. Mol. Pharm. 5, 287 (2008).
60. S. R. Schwarze, and S. F. Dowdy, In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends. Pharmacol. Sci. 21, 45 (2000).
61. M. Lindgren, M. Hallbrink, A. Prochiantz, and U. Langel, Cell-penetrating peptides. Trends. Pharmacol. Sci. 21, 99 (2000).
62. S. R. Schwarze, A. Ho, A. Vocero-Akbani, and S. F. Dowdy, In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285, 1569 (1999).
63. B. R. Meade and S. F. Dowdy, Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59, 134 (2007).
64. E. L. Snyder and S. F. Dowdy, Protein/peptide transduction domains: Potential to deliver large DNA molecules into cells. Curr. Opin. Mol. Ther. 3, 147 (2001).
65. C. Marty, C. Meylan, H. Schott, K. Ballmer-Hofer, and R. A. Schwendener, Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes. Cell Mol. Life Sci. 61, 1785 (2004).
66. J. S. Wadia, R. V. Stan, and S. F. Dowdy, Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310 (2004).
67. E. Vives, P. Brodin, and B. Lebleu, A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272, 16010 (1997).
68. S. Futaki, T. Suzuki, W. Ohashi, T. Yagami, S. Tanaka, K. Ueda, and Y. Sugiura, Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276, 5836 (2001).
69. J. P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M. J. Gait, L. V. Chernomordik, and B. Lebleu, Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278, 585 (2003).
70. R. R. Sawant, R. M. Sawant, A. A. Kale, and V. P. Torchilin, The architecture of ligand attachment to nanocarriers controls their specific interaction with target cells. J. Drug Target. 16, 596 (2008).
71. I. A. Khalil, S. Futaki, M. Niwa, Y. Baba, N. Kaji, H. Kamiya, and H. Harashima, Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: Enhanced cellular association by hydrophobic core formation. Gene Ther. 11, 636 (2004).
72. A. Iwasa, H. Akita, I. Khalil, K. Kogure, S. Futaki, and H. Harashima, Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature. Biochim. Biophys. Acta. 1758, 713 (2006).
73. S. Console, C. Marty, C. Garcia-Echeverria, R. Schwendener, and K. Ballmer-Hofer, Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J. Biol. Chem. 278, 35109 (2003).
74. A. Ferrari, V. Pellegrini, C. Arcangeli, A. Fittipaldi, M. Giacca, and F. Beltram, Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 8, 284 (2003).
75. I. M. Kaplan, J. S. Wadia, and S. F. Dowdy, Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 102, 247 (2005).
76. I. A. Khalil, K. Kogure, S. Futaki, and H. Harashima, High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem. 281, 3544 (2006).
77. R. M. Sawant, J. P. Hurley, S. Salmaso, A. Kale, E. Tolcheva, T. S. Levchenko, and V. P. Torchilin, "SMART" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 17, 943 (2006).
78. R. R. Sawant and V. P. Torchilin, Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int. J. Pharm. 374, 114 (2009).
79. T. Suzuki, S. Futaki, M. Niwa, S. Tanaka, K. Ueda, and Y. Sugiura, Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277, 2437 (2002).
80. J. P. Richard, K. Melikov, E. Vives, C. Ramos, B. Verbeure, M. J. Gait, L. V. Chernomordik, and B. Lebleu, Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278, 585 (2003).
81. I. Nakase, M. Niwa, T. Takeuchi, K. Sonomura, N. Kawabata, Y. Koike, M. Takehashi, S. Tanaka, K. Ueda, J. C. Simpson, A. T. Jones, Y. Sugiura, and S. Futaki, Cellular uptake of arginine-rich peptides: Roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011 (2004).
82. A. El-Sayed, I. A. Khalil, K. Kogure, S. Futaki, and H. Harashima, Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. J. Biol. Chem. 283, 23450 (2008).
83. R. F. Epand, J. C. Martinou, S. Montessuit, R. M. Epand, and C. M. Yip, Direct evidence for membrane pore formation by the apoptotic protein bax. Biochem. Biophys. Res. Commun. 298, 744 (2002).
84. R. Savic, L. Luo, A. Eisenberg, and D. Maysinger, Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 300, 615 (2003).
85. M. Brisson, W. C. Tseng, C. Almonte, S. Watkins, and L. Huang, Subcellular trafficking of the cytoplasmic expression system. Hum. Gene. Ther. 10, 2601 (1999).
86. V. Weissig, S. V. Boddapati, S. M. Cheng, and G. G. D'Souza, Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J. Liposome Res. 16, 249 (2006).
87. F. Vult von Steyern, J. O. Josefsson, and S. Tagerud, Rhodamine B, a fluorescent probe for acidic organelles in denervated skeletal muscle. J. Histochem. Cytochem. 44, 267 (1996).
88. K. Kono, T. Igawa, and T. Takagishi, Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim. Biophys. Acta. 1325, 143 (1997).
89. U. Huth, A. Wieschollek, Y. Garini, R. Schubert, and R. Peschka-Suss, Fourier transformed spectral bio-imaging for studying the intracellular fate of liposomes. Cytometry A 57, 10 (2004).
90. E. Schrock, S. du Manoir, T. Veldman, B. Schoell, J. Wienberg, M. A. Ferguson-Smith, Y. Ning, D. H. Ledbetter, I. Bar-Am, D. Soenksen, Y. Garini, and T. Ried, Multicolor spectral karyotyping of human chromosomes. Science 273, 494 (1996).
91. D. L. Farkas, G. Baxter, R. L. DeBiasio, A. Gough, M. A. Nederlof, D. Pane, J. Pane, D. R. Patek, K. W. Ryan, and D. L. Taylor, Multimode light microscopy and the dynamics of molecules, cells, and tissues. Annu. Rev. Physiol. 55, 785 (1993).
92. M. Bruchez, Jr., M. Moronne, P. Gin, S. Weiss, and A. P. Alivisatos, Semiconductor nanocrystals as fluorescent biological labels. Science 281, 2013 (1998).
93. D. S. Lidke, P. Nagy, R. Heintzmann, D. J. Arndt-Jovin, J. N. Post, H. E. Grecco, E. A. Jares-Erijman, and T. M. Jovin, Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol. 22, 198 (2004).
94. D. S. Lidke and D. J. Arndt-Jovin, Imaging takes a quantum leap. Physiology 19, 322 (2004).
95. T. M. Jovin, Quantum dots finally come of age. Nat. Biotechnol. 21, 32 (2003).
96. D. Maysinger, J. Lovric, A. Eisenberg, and R. Savic, Fate of micelles and quantum dots in cells. Eur. J. Pharm. Biopharm. 65, 270 (2007).
97. I. Rubinstein, I. Soos, and H. Onyuksel, Intracellular delivery of VIP-grafted sterically stabilized phospholipid mixed nanomicelles in human breast cancer cells. Chem. Biol. Interact. 171, 190 (2008).
98. V. Dudu, M. Ramcharan, M. L. Gilchrist, E. C. Holland, and M. Vazquez, Liposome delivery of quantum dots to the cytosol of live cells. J. Nanosci. Nanotechnol. 8, 2293 (2008).
99. W. T. Al-Jamal, K. T. Al-Jamal, B. Tian, L. Lacerda, P. H. Bomans, P. M. Frederik, and K. Kostarelos, Lipid-quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS Nano. 2, 408 (2008).
100. K. C. Weng, C. O. Noble, B. Papahadjopoulos-Sternberg, F. F. Chen, D. C. Drummond, D. B. Kirpotin, D. Wang, Y. K. Hom, B. Hann, and J. W. Park, Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 8, 2851 (2008).
101. W. T. Al-Jamal, K. T. Al-Jamal, P. H. Bomans, P. M. Frederik, and K. Kostarelos, Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 4, 1406 (2008).
102. V. Weissig, S. M. Cheng, and G. G. D'Souza, Mitochondrial pharmaceutics. Mitochondrion. 3, 229 (2004).
103. V. Weissig, S. V. Boddapati, L. Jabr, and G. G. D'Souza, Mitochondria-specific nanotechnology. Nanomed. 2, 275 (2007).
104. S. V. Boddapati, G. G. D'Souza, S. Erdogan, V. P. Torchilin, and V. Weissig, Organelle-targeted nanocarriers: Specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 8, 2559 (2008).
105. J. B. Helms and C. Zurzolo, Lipids as targeting signals: Lipid rafts and intracellular trafficking. Traffic 5, 247 (2004).
106. A. Kheirolomoom and K. W. Ferrara, Cholesterol transport from liposomal delivery vehicles. Biomaterials 28, 4311 (2007).
107. B. D. Moyer and W. E. Balch, A new frontier in pharmacology: The endoplasmic reticulum as a regulated export pathway in health and disease. Expert Opin. Ther. Targets. 5, 165 (2001).
108. G. E. Costin, M. Trif, N. Nichita, R. A. Dwek, and S. M. Petrescu, pH-sensitive liposomes are efficient carriers for endoplasmic reticulum-targeted drugs in mouse melanoma cells. Biochem. Biophys. Res. Commun. 293, 918 (2002).
109. O. Seksek, J. Biwersi, and A. S. Verkman, Direct measurement of trans-golgi pH in living cells and regulation by second messengers. J. Biol. Chem. 270, 4967 (1995).
110. L. M. Bareford and P. W. Swaan, Endocytic mechanisms for targeted drug delivery. Adv. Drug Deliv. Rev. 59, 748 (2007).
111. Y. Rouille, W. Rohn, and B. Hoflack, Targeting of lysosomal proteins. Semin. Cell. Dev. Biol. 11, 165 (2000).
112. S. Muro, E. H. Schuchman, and V. R. Muzykantov, Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis. Mol. Ther. 13, 135 (2006).
113. J. B. Lloyd, Lysosome membrane permeability: Implications for drug delivery. Adv. Drug Deliv. Rev. 41, 189 (2000).